We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Abzena | LSE:ABZA | London | Ordinary Share | GB00BN65QN46 | ORD GBP0.002 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 15.75 | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), a life sciences group providing services and technologies enabling the development and manufacture of biopharmaceutical products, has published its full year results for the year to 31 March 2017.
Corporate highlights
Financial summary
Post-period events
John Burt, CEO of Abzena, commented:
“The past 12 months have been a combination of integration and preparing the Group for significant growth.
“Integration of our US sites into the Abzena Group is starting to deliver the expected revenue synergies. We are increasingly seeing our partners utilise our services on a repeat basis and engage with the range of services across the domains of biology, chemistry and manufacturing. The business now has a solid platform from which to expand.
“The recent fund raising from current and new investors gives us the means to establish the capacity to meet the increasing demand for our integrated services and will accelerate our progress towards profitability.”
For the full release, please visit the company website at www.abzena.com
About Abzena
Abzena (AIM: ABZA) provides proprietary technologies and complementary services to enable the development and manufacture of biopharmaceutical products.
The term ‘ABZENA Inside’ is used by Abzena to describe products that have been created using its proprietary technologies and are being developed by its partners, and include Composite Human Antibodies™ and ThioBridge™ Antibody Drug Conjugates (ADCs). Abzena has the potential to earn future licence fees, milestone payments and/or royalties on ‘ABZENA Inside’ products.
Abzena offers the following services and technologies across its principal sites in Cambridge (UK), San Diego, California (USA) and Bristol, Pennsylvania (USA):
For more information, please see www.abzena.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20170612006378/en/
Abzena plcJohn Burt, +44 1223 903498Chief Executive OfficerorJulian Smith, +44 1223 903498Chief Financial OfficerorNumis (Nominated Adviser and Broker)Clare Terlouw / James Black / Paul Gillam, +44 20 7260 1000orN+1 Singer (Joint Broker)Aubrey Powell / Liz Yong, +44 20 7496 3000orInstinctif PartnersMelanie Toyne Sewell / Alex Shaw, +44 20 7457 2020abzena@instinctif.com
1 Year Abzena Chart |
1 Month Abzena Chart |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions